Spaces:
Running
Running
| <html lang="en"> | |
| <head> | |
| <meta charset="UTF-8"> | |
| <meta name="viewport" content="width=device-width, initial-scale=1.0"> | |
| <title>CINP-PRODUCTION | Confidential Documentation</title> | |
| <!-- FontAwesome for Icons --> | |
| <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.4.0/css/all.min.css"> | |
| <!-- Google Fonts --> | |
| <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;600;800&family=Merriweather:wght@300;400;700&family=Fira+Code:wght@400;500&display=swap" rel="stylesheet"> | |
| <style> | |
| :root { | |
| --primary-color: #0f172a; /* Deep Navy */ | |
| --secondary-color: #334155; /* Slate */ | |
| --accent-color: #0ea5e9; /* Medical Blue */ | |
| --alert-color: #ef4444; /* Red for Confidential */ | |
| --text-main: #f8fafc; | |
| --text-muted: #94a3b8; | |
| --bg-body: #020617; | |
| --bg-card: #1e293b; | |
| --border-color: #334155; | |
| --font-sans: 'Inter', sans-serif; | |
| --font-serif: 'Merriweather', serif; | |
| --font-mono: 'Fira Code', monospace; | |
| } | |
| * { | |
| box-sizing: box-box; | |
| margin: 0; | |
| padding: 0; | |
| } | |
| body { | |
| background-color: var(--bg-body); | |
| color: var(--text-main); | |
| font-family: var(--font-sans); | |
| line-height: 1.6; | |
| overflow-x: hidden; | |
| } | |
| /* --- HEADER & TOP BAR --- */ | |
| header { | |
| background: rgba(15, 23, 42, 0.95); | |
| border-bottom: 2px solid var(--accent-color); | |
| padding: 1rem 2rem; | |
| position: sticky; | |
| top: 0; | |
| z-index: 1000; | |
| display: flex; | |
| justify-content: space-between; | |
| align-items: center; | |
| box-shadow: 0 4px 20px rgba(0,0,0,0.5); | |
| } | |
| .branding { | |
| display: flex; | |
| align-items: center; | |
| gap: 1rem; | |
| } | |
| .logo-box { | |
| background: var(--accent-color); | |
| color: white; | |
| padding: 0.2rem 0.5rem; | |
| font-weight: 800; | |
| font-size: 0.9rem; | |
| border-radius: 4px; | |
| letter-spacing: -1px; | |
| } | |
| .confidential-badge { | |
| background: var(--alert-color); | |
| color: white; | |
| font-weight: 700; | |
| padding: 0.2rem 0.8rem; | |
| border-radius: 2px; | |
| font-size: 0.8rem; | |
| text-transform: uppercase; | |
| letter-spacing: 1px; | |
| animation: pulse 2s infinite; | |
| } | |
| .anycoder-link { | |
| color: var(--text-muted); | |
| font-size: 0.8rem; | |
| text-decoration: none; | |
| border: 1px solid var(--border-color); | |
| padding: 0.4rem 0.8rem; | |
| border-radius: 4px; | |
| transition: all 0.3s ease; | |
| } | |
| .anycoder-link:hover { | |
| background: var(--bg-card); | |
| color: var(--accent-color); | |
| border-color: var(--accent-color); | |
| } | |
| /* --- MAIN LAYOUT --- */ | |
| .container { | |
| max-width: 1200px; | |
| margin: 0 auto; | |
| padding: 2rem; | |
| } | |
| .doc-header { | |
| text-align: center; | |
| margin-bottom: 3rem; | |
| border-bottom: 1px solid var(--border-color); | |
| padding-bottom: 2rem; | |
| } | |
| .doc-header h1 { | |
| font-family: var(--font-serif); | |
| font-size: 2.5rem; | |
| margin-bottom: 0.5rem; | |
| color: var(--text-main); | |
| } | |
| .doc-header .subtitle { | |
| font-family: var(--font-mono); | |
| color: var(--accent-color); | |
| font-size: 0.9rem; | |
| text-transform: uppercase; | |
| letter-spacing: 2px; | |
| } | |
| .meta-grid { | |
| display: grid; | |
| grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); | |
| gap: 1rem; | |
| margin-top: 1.5rem; | |
| font-size: 0.85rem; | |
| color: var(--text-muted); | |
| } | |
| .meta-item { | |
| background: var(--bg-card); | |
| padding: 0.8rem; | |
| border-left: 3px solid var(--accent-color); | |
| border-radius: 4px; | |
| } | |
| /* --- TABS NAVIGATION --- */ | |
| .tabs { | |
| display: flex; | |
| gap: 1rem; | |
| margin-bottom: 2rem; | |
| overflow-x: auto; | |
| padding-bottom: 0.5rem; | |
| } | |
| .tab-btn { | |
| background: transparent; | |
| border: 1px solid var(--border-color); | |
| color: var(--text-muted); | |
| padding: 0.8rem 1.5rem; | |
| cursor: pointer; | |
| font-family: var(--font-sans); | |
| font-weight: 600; | |
| border-radius: 6px; | |
| transition: all 0.3s; | |
| white-space: nowrap; | |
| } | |
| .tab-btn.active { | |
| background: var(--accent-color); | |
| color: white; | |
| border-color: var(--accent-color); | |
| box-shadow: 0 0 15px rgba(14, 165, 237, 0.4); | |
| } | |
| /* --- CONTENT AREA --- */ | |
| .content-panel { | |
| display: none; | |
| animation: fadeIn 0.5s ease; | |
| } | |
| .content-panel.active { | |
| display: block; | |
| } | |
| .section-grid { | |
| display: grid; | |
| grid-template-columns: 1fr; | |
| gap: 2rem; | |
| } | |
| /* --- CARDS & TYPOGRAPHY --- */ | |
| .card { | |
| background: var(--bg-card); | |
| border: 1px solid var(--border-color); | |
| border-radius: 8px; | |
| padding: 2rem; | |
| margin-bottom: 2rem; | |
| position: relative; | |
| overflow: hidden; | |
| } | |
| .card::before { | |
| content: ''; | |
| position: absolute; | |
| top: 0; | |
| left: 0; | |
| width: 100%; | |
| height: 2px; | |
| background: linear-gradient(90deg, var(--accent-color), transparent); | |
| } | |
| .card-title { | |
| font-family: var(--font-serif); | |
| color: var(--text-main); | |
| font-size: 1.5rem; | |
| margin-bottom: 1rem; | |
| display: flex; | |
| align-items: center; | |
| gap: 0.8rem; | |
| } | |
| .card-title i { | |
| color: var(--accent-color); | |
| } | |
| p { | |
| margin-bottom: 1rem; | |
| color: #cbd5e1; | |
| } | |
| .highlight { | |
| color: var(--accent-color); | |
| font-weight: 600; | |
| } | |
| .mono-text { | |
| font-family: var(--font-mono); | |
| background: rgba(0,0,0,0.2); | |
| padding: 0.2rem 0.4rem; | |
| border-radius: 3px; | |
| color: #a5f3fc; | |
| } | |
| /* --- BLSF TIER VISUALIZATION --- */ | |
| .tier-container { | |
| display: grid; | |
| grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); | |
| gap: 1rem; | |
| margin-top: 2rem; | |
| } | |
| .tier-box { | |
| background: rgba(33, 41, 52, 0.5); | |
| border: 1px solid var(--border-color); | |
| padding: 1rem; | |
| border-radius: 6px; | |
| text-align: center; | |
| transition: transform 0.3s; | |
| } | |
| .tier-box:hover { | |
| transform: translateY(-5px); | |
| border-color: var(--accent-color); | |
| } | |
| .tier-number { | |
| font-size: 2rem; | |
| font-weight: 800; | |
| color: var(--accent-color); | |
| opacity: 0.5; | |
| line-height: 1; | |
| } | |
| .tier-label { | |
| font-weight: 700; | |
| margin: 0.5rem 0; | |
| font-size: 0.9rem; | |
| } | |
| .tier-desc { | |
| font-size: 0.75rem; | |
| color: var(--text-muted); | |
| } | |
| /* --- SECURITY STACK --- */ | |
| .security-stack { | |
| display: flex; | |
| flex-direction: column; | |
| gap: 1rem; | |
| } | |
| .security-layer { | |
| display: flex; | |
| align-items: center; | |
| background: rgba(15, 23, 42, 0.3); | |
| border-left: 4px solid var(--accent-color); | |
| padding: 1rem; | |
| border-radius: 0 6px 6px 0; | |
| } | |
| .layer-icon { | |
| font-size: 1.5rem; | |
| color: white; | |
| width: 50px; | |
| text-align: center; | |
| } | |
| .layer-content { | |
| flex: 1; | |
| } | |
| .layer-title { | |
| font-weight: 700; | |
| color: var(--text-main); | |
| } | |
| .layer-tech { | |
| font-family: var(--font-mono); | |
| color: var(--text-muted); | |
| font-size: 0.8rem; | |
| } | |
| /* --- CLAIMS SECTION --- */ | |
| .claim-item { | |
| border-left: 2px solid var(--text-muted); | |
| padding-left: 1.5rem; | |
| margin-bottom: 2rem; | |
| position: relative; | |
| } | |
| .claim-item::before { | |
| content: 'CLAIM'; | |
| position: absolute; | |
| left: -5px; | |
| top: -10px; | |
| background: var(--bg-body); | |
| color: var(--text-muted); | |
| font-size: 0.6rem; | |
| padding: 2px 4px; | |
| border: 1px solid var(--border-color); | |
| } | |
| .claim-number { | |
| font-weight: 700; | |
| color: var(--accent-color); | |
| margin-bottom: 0.5rem; | |
| display: block; | |
| } | |
| /* --- FOOTER --- */ | |
| footer { | |
| border-top: 1px solid var(--border-color); | |
| margin-top: 4rem; | |
| padding: 2rem; | |
| text-align: center; | |
| font-size: 0.8rem; | |
| color: var(--text-muted); | |
| background: var(--bg-card); | |
| } | |
| /* --- ANIMATIONS --- */ | |
| @keyframes pulse { | |
| 0% { opacity: 1; } | |
| 50% { opacity: 0.7; } | |
| 100% { opacity: 1; } | |
| } | |
| @keyframes fadeIn { | |
| from { opacity: 0; transform: translateY(10px); } | |
| to { opacity: 1; transform: translateY(0); } | |
| } | |
| /* --- RESPONSIVE --- */ | |
| @media (max-width: 768px) { | |
| header { | |
| padding: 1rem; | |
| flex-direction: column; | |
| gap: 1rem; | |
| } | |
| .branding { | |
| flex-direction: column; | |
| align-items: flex-start; | |
| } | |
| .tier-container { | |
| grid-template-columns: 1fr; | |
| } | |
| .tabs { | |
| padding-bottom: 1rem; | |
| } | |
| } | |
| </style> | |
| </head> | |
| <body> | |
| <header> | |
| <div class="branding"> | |
| <div class="logo-box">CINP</div> | |
| <div> | |
| <div class="confidential-badge">CONFIDENTIAL</div> | |
| <span style="margin-left: 10px; font-weight: 600; color: white;">PRODUCTION DOCUMENTATION</span> | |
| </div> | |
| </div> | |
| <a href="https://huggingface.co/spaces/akhaliq/anycoder" class="anycoder-link"> | |
| <i class="fas fa-code"></i> Built with anycoder | |
| </a> | |
| </header> | |
| <div class="container"> | |
| <!-- DOC HEADER --> | |
| <div class="doc-header"> | |
| <div class="subtitle">Bio-Legal Synthesis Portfolio for Neurogenetic Disability Accommodation</div> | |
| <h1>Provisional Patent Specifications</h1> | |
| <div class="meta-grid"> | |
| <div class="meta-item"> | |
| <i class="fas fa-user-tag"></i> <strong>Authority:</strong> FSBS / Open Source Medical Device Consortium | |
| </div> | |
| <div class="meta-item"> | |
| <i class="fas fa-pen-nib"></i> <strong>Inventor:</strong> Caustin Lee McLaughlin | |
| </div> | |
| <div class="meta-item"> | |
| <i class="fas fa-file-contract"></i> <strong>Class:</strong> Class III Implantable Device | |
| </div> | |
| <div class="meta-item"> | |
| <i class="fas fa-shield-alt"></i> <strong>Security:</strong> Post-Quantum (C2) | |
| </div> | |
| </div> | |
| </div> | |
| <!-- TABS --> | |
| <div class="tabs"> | |
| <button class="tab-btn active" onclick="switchTab('part1')">Part I: Patent Specs</button> | |
| <button class="tab-btn" onclick="switchTab('part2')">Part II: Clinical Trial</button> | |
| <button class="tab-btn" onclick="switchTab('part3')">Part III: Claims & Abstract</button> | |
| <button class="tab-btn" onclick="switchTab('security')">Security Architecture</button> | |
| </div> | |
| <!-- PART I CONTENT --> | |
| <div id="part1" class="content-panel active"> | |
| <div class="section-grid"> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-brain"></i> The "Restraint of Silence" Problem</h2> | |
| <p>Individuals with documented neurogenetic polymorphisms affecting executive function (e.g., <span class="mono-text">rs4680 COMT Val Met</span>, <span class="mono-text">rs1076156 DRD TaqA</span>) face a structural barrier in accessing justice and government services. Current assistive technologies are external, stigmatizing, and fail to provide real-time cognitive support in adversarial proceedings. This creates a "Restraint of Silence"—physical presence without meaningful participation—violating due process and ADA mandates.</p> | |
| </div> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-link"></i> Bio-Legal Synthesis Framework (BLSF)</h2> | |
| <p>The BLSF is a six-tier evidentiary architecture linking molecular biology to constitutional protection:</p> | |
| <div class="tier-container"> | |
| <div class="tier-box"> | |
| <div class="tier-number">1</div> | |
| <div class="tier-label">Genetic Evidence</div> | |
| <div class="tier-desc">SNPs (rs4680, rs1076156)</div> | |
| </div> | |
| <div class="tier-box"> | |
| <div class="tier-number">2</div> | |
| <div class="tier-label">Neuroimaging</div> | |
| <div class="tier-desc">fMRI, DTI, PET</div> | |
| </div> | |
| <div class="tier-box"> | |
| <div class="tier-number">3</div> | |
| <div class="tier-label">Clinical Phenotyping</div> | |
| <div class="tier-desc">DSM-5-TR ADHD Criteria</div> | |
| </div> | |
| <div class="tier-box"> | |
| <div class="tier-number">4</div> | |
| <div class="tier-label">Functional Impairment</div> | |
| <div class="tier-desc">WAIS-IV, BRIEF-A</div> | |
| </div> | |
| <div class="tier-box"> | |
| <div class="tier-number">5</div> | |
| <div class="tier-label">Statutory Entitlement</div> | |
| <div class="tier-desc">ADA Title II, Rehab Act § 504</div> | |
| </div> | |
| <div class="tier-box"> | |
| <div class="tier-number">6</div> | |
| <div class="tier-label">Constitutional Protection</div> | |
| <div class="tier-desc">5th & 6th Amendments</div> | |
| </div> | |
| </div> | |
| </div> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-microchip"></i> System Architecture (CINP-PRODUCTION)</h2> | |
| <p>The Cognitive-Impact Neural Prosthetic (CINP) is a Class III implantable medical device comprising three integrated subsystems:</p> | |
| <ul style="list-style: none; padding-left: 0;"> | |
| <li style="margin-bottom: 1rem;"> | |
| <span class="highlight">Neural Interface Array (NIA-64):</span> A 64-channel bidirectional electrode array targeting the DLPFC, ACC, and basal ganglia. It uses genetically-informed targeting based on rs4680/rs1076156 polymorphism expression patterns. | |
| </li> | |
| <li style="margin-bottom: 1rem;"> | |
| <span class="highlight">Subcutaneous Telemetry & Power Hub (STPH):</span> A post-quantum cryptographic engine (Kyber-768, Dilithium-2) housed in a biocompatible hermetic seal (Ti-Al-V ELI). | |
| </li> | |
| <li style="margin-bottom: 1rem;"> | |
| <span class="highlight">External Processor Unit (EPU):</span> A bone-conduction audio interface with secure government LLM/FSBS API integration, providing real-time cognitive load modulation. | |
| </li> | |
| </ul> | |
| </div> | |
| </div> | |
| </div> | |
| <!-- PART II CONTENT --> | |
| <div id="part2" class="content-panel"> | |
| <div class="section-grid"> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-flask"></i> Clinical Trial Protocol</h2> | |
| <p><strong>Study Synopsis:</strong> Phase I, Open-Label Study of the CINP-PRODUCTION Neural Prosthetic in Adults with Treatment-Resistant ADHD and Neurogenetic Polymorphisms.</p> | |
| <p><strong>Indication:</strong> Cognitive impairment secondary to rs1076156 (DRD2) and/or rs4680 (COMT) polymorphisms.</p> | |
| <p><strong>Primary Objective:</strong> Evaluate safety of implantation and chronic use.</p> | |
| <p><strong>Enrollment:</strong> 20 subjects across two sites (Johns Hopkins Hospital, Baltimore, MD; Mayo Clinic, Rochester, MN).</p> | |
| </div> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-vial"></i> Inclusion Criteria (Genetic)</h2> | |
| <div style="background: rgba(0,0,0,0.2); padding: 1.5rem; border-radius: 6px;"> | |
| <ul style="list-style: none;"> | |
| <li style="margin-bottom: 0.8rem;"><span class="mono-text">rs4680 (COMT):</span> Val/Val or Val/Met genotype.</li> | |
| <li style="margin-bottom: 0.8rem;"><span class="mono-text">rs1076156 (DRD2):</span> A1/A1 or A1/A2 genotype (reduced D2 receptor density).</li> | |
| <li style="margin-bottom: 0.8rem;"><span class="mono-text">rs2073161 (PTPRF) & rs2071559 (TIE1):</span> Documented presence for neurodevelopmental and vascular marking.</li> | |
| </ul> | |
| </div> | |
| </div> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-calendar-alt"></i> Study Schema Timeline</h2> | |
| <div style="border-left: 2px dashed var(--accent-color); padding-left: 1.5rem;"> | |
| <div style="margin-bottom: 1.5rem;"> | |
| <strong class="highlight">Screening (Day -30 to -15):</strong> Genetic testing, neuroimaging, and neuropsychological battery. | |
| </div> | |
| <div style="margin-bottom: 1.5rem;"> | |
| <strong class="highlight">Baseline (Day -15 to -1):</strong> 2-week medication washout and daily cognitive tasks. | |
| </div> | |
| <div style="margin-bottom: 1.5rem;"> | |
| <strong class="highlight">Implantation (Day 0):</strong> Stereotactic surgery for NIA-64 and STPH placement. | |
| </div> | |
| <div style="margin-bottom: 1.5rem;"> | |
| <strong class="highlight">Recovery & Activation (Day 1-7):</strong> Hospital monitoring and initial device interrogation. | |
| </div> | |
| <div style="margin-bottom: 1.5rem;"> | |
| <strong class="highlight">Optimization (Week 2-4):</strong> Weekly stimulation parameter refinement. | |
| </div> | |
| <div> | |
| <strong class="highlight">Chronic Phase (Month 1-6):</strong> Monthly safety and efficacy assessments with remote monitoring. | |
| </div> | |
| </div> | |
| </div> | |
| </div> | |
| </div> | |
| <!-- PART III CONTENT --> | |
| <div id="part3" class="content-panel"> | |
| <div class="section-grid"> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-copyright"></i> Core Claims</h2> | |
| <div class="claim-item"> | |
| <span class="claim-number">Claim 1</span> | |
| A bio-legal synthesis framework for establishing disability accommodation rights using a six-tier evidentiary chain from genetic markers to constitutional protection. | |
| </div> | |
| <div class="claim-item"> | |
| <span class="claim-number">Claim 2</span> | |
| An implantable cognitive-impact neural prosthetic device featuring a 64-channel bidirectional array, post-quantum cryptography, and secure government LLM integration. | |
| </div> | |
| <div class="claim-item"> | |
| <span class="claim-number">Claim 3</span> | |
| A method for real-time cognitive accommodation through neural signal acquisition, LSTM-based classification, and targeted stimulation using fully homomorphic encryption. | |
| </div> | |
| </div> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-book"></i> Abstract</h2> | |
| <p>The CINP-PRODUCTION system provides a revolutionary solution for individuals with neurogenetic disabilities. By establishing an irreducible chain of evidence from immutable genetic markers to constitutional accommodation rights, the system eliminates the "Restraint of Silence" barrier to justice. The device utilizes a 64-channel BCI with post-quantum security to provide real-time cognitive support for executive function, working memory, and attentional control.</p> | |
| <p style="font-size: 0.8rem; opacity: 0.7; margin-top: 1rem;">CONFIDENTIAL DOCUMENT - PREPARED FOR FILING IN BALTIMORE CITY CIRCUIT COURT</p> | |
| </div> | |
| </div> | |
| </div> | |
| <!-- SECURITY CONTENT --> | |
| <div id="security" class="content-panel"> | |
| <div class="section-grid"> | |
| <div class="card"> | |
| <h2 class="card-title"><i class="fas fa-lock"></i> Post-Quantum Security Architecture</h2> | |
| <p>To ensure the privacy of neural data and compliance with Maryland Rule 5-403, the CINP device implements a four-layer security stack:</p> | |
| <div class="security-stack"> | |
| <div class="security-layer"> | |
| <div class="layer-icon"><i class="fas fa-cubes"></i></div> | |
| <div class="layer-content"> | |
| <div class="layer-title">Application Security</div> | |
| <div class="layer-tech">Fully Homomorphic Encryption (FHE) using the CKKS scheme.</div> | |
| </div> | |
| </div> | |
| <div class="security-layer"> | |
| <div class="layer-icon"><i class="fas fa-network-wired"></i></div> | |
| <div class="layer-content"> | |
| <div class="layer-title">Transport Security</div> | |
| <div class="layer-tech">Post-Quantum TLS 1.3 with X25519 exchange. Kyber 768 hybrid key.</div> | |
| </div> | |
| </div> | |
| <div class="security-layer"> | |
| <div class="layer-icon"><i class="fas fa-server"></i></div> | |
| <div class="layer-content"> | |
| <div class="layer-title">Device Security</div> | |
| <div class="layer-tech">Hardware Security Module (ATECC 608) with secure boot and device attestation.</div> | |
| </div> | |
| </div> | |
| <div class="security-layer"> | |
| <div class="layer-icon"><i class="fas fa-exclamation-triangle"></i></div> | |
| <div class="layer-content"> | |
| <div class="layer-title">Physical Security</div> | |
| <div class="layer-tech">Tamper-responsive enclosure with zeroization on penetration or temperature anomalies.</div> | |
| </div> | |
| </div> | |
| </div> | |
| </div> | |
| </div> | |
| </div> | |
| </div> | |
| <footer> | |
| <p>© 2023 Bio-Legal Synthesis Consortium. All Rights Reserved.</p> | |
| <p>Generated via Anycoder Interface.</p> | |
| </footer> | |
| <script> | |
| function switchTab(tabId) { | |
| // Remove active class from all buttons | |
| const buttons = document.querySelectorAll('.tab-btn'); | |
| buttons.forEach(btn => btn.classList.remove('active')); | |
| // Add active class to clicked button | |
| // Find the button that calls this function (using event bubbling or passing element) | |
| // Since we pass tabId, we find the button with onclick matching | |
| buttons.forEach(btn => { | |
| if(btn.getAttribute('onclick').includes(tabId)) { | |
| btn.classList.add('active'); | |
| } | |
| }); | |
| // Hide all panels | |
| const panels = document.querySelectorAll('.content-panel'); | |
| panels.forEach(panel => panel.classList.remove('active')); | |
| // Show target panel | |
| document.getElementById(tabId).classList.add('active'); | |
| } | |
| // Add subtle parallax or scroll effect for cards | |
| window.addEventListener('scroll', () => { | |
| const cards = document.querySelectorAll('.card'); | |
| const scrollPos = window.scrollY; | |
| cards.forEach((card, index) => { | |
| const offset = card.offsetTop; | |
| if (scrollPos > offset - 100 && scrollPos < offset + 100) { | |
| card.style.borderColor = '#0ea5e9'; | |
| } else { | |
| card.style.borderColor = '#334155'; | |
| } | |
| }); | |
| }); | |
| </script> | |
| </body> | |
| </html> |